USPTO serial 79290136
NOAELPLATIN
Reviewed by CopyMark Law Group
Reg. 6398898Status 404
- Filing date
- Status date
- Registration date
- Jun 29, 2021
- Examiner
- SEVERSON, JUSTIN
- Law office
- TMO LAW OFFICE 100 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NOAELPLATIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lenny R. Jiang
Lenny R. Jiang Paratus Law Group, PLLC1765 Greensboro Station PlaceSuite 320Tysons Corner, VA 22102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of pancreatic tumors; pharmaceutical agents for the treatment of disorders in sensory organs; thyroid and para-thyroid hormone preparations; medicinal tonics for the treatment of pancreatic tumors; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents for use in regulating metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anesthetics; pharmaceutical for use in the treating disorders of the peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms for medical purposes; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for treating disorders of the urogenital organs; vitamin preparations; pharmaceutical preparations for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents for treating disorders of the digestive organs; pharmaceutical preparations for the treatment of cardiovascular disorders; nervines; ophthalmic preparations; allergy medications; chemico-pharmaceutical preparations for the treatment of pancreatic disorders; medicines for the treatment of gastrointestinal diseases; mineral injection preparations featuring vitamin supplements for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; laxative suppositories; pharmaceutical preparations for use in the treatment of disorders of the central nervous system; pharmaceutical preparations for diagnosis of cancer; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for treating tooth pain; hemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for treatment of hemorrhoids; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood solvent being preparations for treating blood disorders; pharmaceutical preparations for treating disorders of the respiratory organs; respiratory stimulant preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for the treatment of rhinitis; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cancerous cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated preparations for the treatment of mouth disorders; transdermal patches for medical treatment of nausea; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of gout; drug delivery agents in the form of dissolvable films, coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 20, 2022 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Mar 20, 2022 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Nov 23, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 28, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 28, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 29, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 3, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 12, 2021 | CORV | REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED | — |
| Jun 29, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 19, 2021 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Apr 13, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 13, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 12, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 24, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 24, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 9, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 4, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 2, 2021 | ALIE | ASSIGNED TO LIE | — |
| Dec 1, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 8, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 21, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 21, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 24, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 28, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 24, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |